Get started

Healthcare

In the Genes for GH’s Path.Guardant Health is building strong bullish momentum, with a gap forming around the $21.50 level. A breakout above the $26.37 resistance would signal further upward movement, targeting the $37.05 weekly resistance. With an appealing 3.6 risk-to-reward ratio, this trade offers an attractive short-term opportunity, while a stop-loss at $19.19 ensures effective risk management. In the longer term, Guardant Health’s bullish outlook could extend to $41.06, supported by its advancements in precision oncology and liquid biopsy technology. With growing adoption of early cancer detection and genomic testing, Guardant Health is positioned to capture increased market share as demand for cutting-edge diagnostics rises. For those with a longer-term view, holding with a $19.19 stop-loss provides an opportunity to capture potential upside while managing downside risk. This combination of technical momentum and Guardant Health’s strong positioning in the healthcare innovation space supports a bullish push toward $37.05, with a longer-term target of $41.06.
NASDAQ:GHLong
by The_Trading_Mechanic
Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name during the pandemic, now faces a pivotal moment. Activist investor Starboard Value has taken a $1 billion stake, signaling potential changes on the horizon. But what does this mean for Pfizer's future? The company that swiftly developed a COVID-19 vaccine now grapples with declining sales and a tumbling stock price. Starboard's involvement brings both challenge and opportunity. Will this be the catalyst for Pfizer's renaissance or a sign of deeper troubles ahead? Former Pfizer executives have been approached to assist in the turnaround effort. Their potential involvement adds an intriguing layer to this unfolding story. Could their experience and insight be the key to unlocking Pfizer's next chapter of success and innovation? As the pharmaceutical landscape evolves post-pandemic, Pfizer's response to this pressure could set industry trends. Cost-cutting, strategic refocusing and potential leadership changes loom large. How will these moves impact drug development, patient care, and the broader healthcare ecosystem? For investors, patients, and industry watchers, Pfizer's next moves are crucial. Will the company emerge stronger, leaner, and more innovative? Or will it struggle to find its footing in a rapidly changing market? The answers to these questions could reshape the future of global healthcare.
NYSE:PFELong
by signalmastermind
Walgreens Boots Alliance (WBA) is gearing up for a potent ...Walgreens Boots Alliance (WBA) is gearing up for a potential breakout, presenting an enticing opportunity for investors. Recent news indicates that Walgreens is restructuring its business model and focusing on cost-cutting measures, which could significantly enhance profitability. Additionally, the company's efforts to expand its healthcare services and improve in-store experiences align well with market trends, making it well-positioned for growth. As analysts project a possible 15% surge in the stock price, now may be the time to consider WBA as a solid investment. BOOOOOOOOOOOM...
NASDAQ:WBALong
by Maximus20000
Agape ATP Launches ATP2, the Future of Health for Ultimate VitalNow Enhanced with 76 Essential Minerals, 20 Amino Acids, and Advanced Enzymes to Support Overall Wellness KUALA LUMPUR, 23 SEPTEMBER 2024 – NASDAQ-listed AGAPE ATP Corporation ("ATPC"), through its subsidiary, AGAPE Superior Living Sdn. Bhd (“ASL”)., proudly unveils the enhanced version of its wellness flagship supplement, ATP2. This groundbreaking product, improved with advanced scientific developments, is designed to address key health challenges including aging, metabolism, and chronic disease management. ATP2 represents a significant advancement in nutritional science, offering a holistic approach to improving health, boosting energy, and supporting overall well-being. At the launch, ATPC announced that the company is targeting to sell 5,000 units by the end of the year, driven by the product’s unique blend of plant-based enzymes, minerals, amino acids, and cutting-edge hydrogen acetate technology. ATPC is confident that demand will surge as consumers increasingly seek natural solutions to improve their health and vitality. Dr. Fernando Cortizo, the President of Research and Development Team of ASL, said, "The future of nutrition is in our ability to reverse the effects of chronic diseases and aging. ATP2 is a supplement which embodies this vision, combining cutting-edge science with a powerful mix of enzymes, minerals, and amino acids. ATP2 is designed to tackle a variety of health concerns. Its unique formulation supports increased energy production by enhancing Nicotinamide Adenine Dinucleotide (“NADH+”) levels in the body.” ATP2’s enhanced formula integrates an advanced blend of cutting-edge ingredients that include plant-based enzymes, 76 essential minerals, and 20 amino acids, all working synergistically with its core ingredient, hydrogen acetate, a unique component that has been scientifically proven to improve metabolism, reduce inflammation, and assist in reversing the effects of aging. The added ingredient works more effectively to increase cellular health, regulate key bodily functions, and support long-term vitality. Prof Dato' Sri Dr How Kok Choong, the Founder and Global Group CEO of ATPC, said, "ATP2 plays a critical role in managing blood pressure and blood sugar levels, promoting cardiovascular health and improving gut flora. The product’s anti-aging properties come from its ability to enhance cellular repair, reduce oxidative stress, and stabilize genome function, helping users maintain a youthful, energetic state as they age.” How added, “This product is a major milestone for ATPC. It reflects our ongoing commitment to innovation in wellness. ATP2’s comprehensive formula addresses some of the most significant health challenges today. With its ability to improve metabolism, manage chronic conditions, and support anti-aging, ATP2 stands out as a transformative solution for anyone looking to enhance their overall health." The product is locally manufactured, in Malaysia, ensuring the highest quality control, while its formulation incorporates advanced technologies from Australia, the USA, Europe, and Japan. By bringing production closer to home, ATPC can ensure a steady supply of ATP2 to meet consumer demand while maintaining superior quality standards. As part of ATPC’s mission to align with the UN Sustainable Development Goals (“UNSDG”), particularly in health and well-being, ATP2 is positioned to make a lasting impact on the wellness market. By offering a scientifically backed solution that addresses common health concerns, ATPC reaffirms its role as a leader in sustainable, innovative wellness solutions.
ALong
by HASHInvests200
Can AI Revolutionize Healthcare?The convergence of artificial intelligence (AI) and healthcare is ushering in a new era of medical innovation. As AI models continue to evolve, their potential to revolutionize patient care becomes increasingly evident. Google's Med-Gemini, a family of AI models specifically tailored for medical applications, represents a significant leap forward in this direction. Google's Med-Gemini's advanced capabilities, including its ability to process complex medical data, reason effectively, and understand long-form text, have the potential to transform various aspects of healthcare. From generating radiology reports to analyzing pathology slides and predicting disease risk, Med-Gemini's applications are vast and far-reaching. However, the integration of AI into healthcare raises important ethical considerations. As AI models become more sophisticated, it is crucial to address concerns related to bias, privacy, and the potential for job displacement. A balanced approach that emphasizes human-AI collaboration is essential to ensure that AI is used to augment rather than replace human expertise. The future of healthcare is undoubtedly intertwined with the advancement of AI. By harnessing the power of AI, we can unlock new possibilities for improving patient outcomes, enhancing medical research, and revolutionizing the way we deliver healthcare. As we continue to explore the potential of AI in medicine, it is imperative to approach this journey with a sense of both excitement and responsibility.
NASDAQ:GOOGLong
by signalmastermind
MAXHEALTH - It is time for 1000?As always, the chart is easy to read and understand. Here are a couple of highlights for this case study: Observed a strong breakout with a long candle, currently in a retest phase. Recent price action shows a clear buyer bias. Key support levels are holding at 892 and 864. The 21-weekly EMA provides additional support. Volume spiked significantly in the last two weeks. The healthcare sector is trending upward. The first major resistance level to watch is around the 1000 mark. Disclaimer: This analysis is for educational purposes only and should not be considered as financial advice or a recommendation to buy, sell, or hold any securities. The information provided is based on historical data and market observations and does not guarantee future performance. Please conduct your own research or consult with a financial advisor before making any investment decisions. Trading in the stock market involves risk, and past performance is not indicative of future results.
NSE:MAXHEALTH
by TheChartereds
Eli Lilly's Zepbound: A Game-Changer for Obesity Treatment?In a groundbreaking move that could redefine the landscape of obesity treatment, Eli Lilly has slashed the price of its weight loss drug, Zepbound, by half. But is this simply a strategic business decision, or is it a beacon of hope for millions struggling with obesity? Join us as we delve into the implications of this bold move and explore the potential impact on the future of weight management. Imagine a world where obesity is no longer a daunting, insurmountable challenge. A world where effective, affordable treatments are accessible to all who need them. Eli Lilly's recent announcement of a significant price reduction for Zepbound brings us closer to that reality. By making this groundbreaking decision, Eli Lilly has not only demonstrated its commitment to patient access but has also sent a powerful message to the broader healthcare industry. This move has the potential to disrupt the status quo, challenging the outdated policies and practices that have hindered progress in obesity treatment. As we explore the implications of Eli Lilly's decision, we must consider the broader context of the obesity epidemic. For decades, obesity has been stigmatized and overlooked as a serious medical condition. Many individuals struggling with weight loss have faced limited treatment options and significant financial burdens. Eli Lilly's move to lower the price of Zepbound could be a game-changer in this regard. By making the drug more affordable, the company is empowering patients to take control of their health and pursue a healthier lifestyle. This could lead to a significant increase in the number of people seeking treatment for obesity, ultimately improving public health outcomes. However, it is important to note that this is just one step in a larger journey. While Eli Lilly's decision is undoubtedly a positive development, more needs to be done to address the systemic issues that contribute to the obesity epidemic. Policymakers, healthcare providers, and communities must work together to create a supportive environment that promotes healthy eating, physical activity, and access to affordable, effective treatments. In conclusion, Eli Lilly's announcement of a price reduction for Zepbound represents a significant milestone in the fight against obesity. By making this drug more accessible, the company is not only helping individuals achieve their weight loss goals but also challenging the broader healthcare system to prioritize obesity treatment.
NYSE:LLYLong
by signalmastermind
CVS - CVS Health: If the stock drops a few points, I'll be buyiIf the stock drops a few points, I'll be buying very heavily... CVS and WBA are in the same sector. And both have been decimated. CVS, however, is doing better. And they're paying a dividend. Target, at least +10%. Trading at 70% below estimate of its fair value Earnings are forecast to grow 9% per year Earnings grew by 140% over the past year DIVIDEND = Pays a high and reliable dividend of 4.75% Trading at good value compared to peers and industry Analysts in good agreement that stock price will rise by 20%
NYSE:CVSLong
by Maximus20000
Centene Corp | CNC | Long at $65As a managed health care company, Centene Corp NYSE:CNC doesn't get much attention. However, it is an undervalued growth stock. It's been a workhorse historically for slow and steady financial returns with a 3%+ dividend. The biggest dips along my selected moving average have been into the blue lines - which it recently tested. While the stock may close the gap near $62 is the near future, it's a personal buy at $65. Target 1 = $78.00 Target 2 = $95.00
NYSE:CNCLong
by NicksAnalysis
1
GE HealthCare | GEHCGE Healthcare aka GEHC is a renowned global medical technology, pharmaceutical diagnostics, and digital solutions company that aims to revolutionize healthcare by eliminating limits. With a diverse portfolio of innovative products, services, and solutions, GEHC empowers healthcare professionals to make informed decisions quickly and improve patient care across the entire healthcare continuum. This article delves into the key aspects of GE Healthcare, including its business segments, macro trends driving growth, management incentives, financial performance, competitors, and valuation. GE Healthcare operates in four business segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. These segments cater to healthcare providers and researchers worldwide, offering a wide range of products and solutions that enhance clinical decision-making and patient outcomes. The company's revenue streams come from the sale of medical devices, consumable products, services, and digital solutions. By focusing on customer-driven innovation, industry-leading service capabilities, and integrated digital solutions, GEHC continually improves the performance, quality, and customer experience of its offerings. GE Healthcare benefits from several macro trends that are shaping the healthcare industry. The growing adoption of precision health, fueled by advancements in genomics, personalized medicine, and targeted therapies, presents opportunities for GEHC to develop tailored solutions. The global precision medicine market is projected to reach $278.3 billion by 2027, with a CAGR of 10.5%. Additionally, the market for genomic testing is expected to reach $30.9 billion by 2027, growing at a CAGR of 14.7%. The digitization of healthcare through AI and machine learning enables the analysis of vast amounts of patient data for more accurate diagnoses and treatment decisions. The global healthcare artificial intelligence market is predicted to reach $31.3 billion by 2025, growing at a CAGR of 41.5%. Furthermore, increasing demand for healthcare services driven by demographic trends and improving access to healthcare in emerging markets further support GEHC's growth trajectory. With personalized medicine estimated to have a market value of $3,168.0 billion by 2027, GEHC is well positioned to leverage these trends and provide innovative solutions to meet the evolving needs of the healthcare industry (Sources: Grand View Research, Fortune Business Insights, Allied Market Research, MarketsandMarkets). GEHC CEO, Peter J. Arduini, has improved incentives in place to drive the company's performance. With an amended offer letter, Arduini's base salary increased to $1,250,000, accompanied by an annual target bonus of 150% of his base salary and an annual long-term incentive grant target of $11,875,000 starting in 2023. These incentives provide a strong motivation for Arduini to lead GEHC's growth and success, enhancing shareholder value. In 2022, GEHC reported total revenue of $18.34 billion, representing a favorable increase compared to the previous year. Although the profitability declined in the final quarter, the company's operating cash flow and adjusted EBIT margin showed positive trends. GEHC guided organic revenue growth of 5% to 7% for 2023, along with higher adjusted EBIT margin and EPS ranges. The company's commitment to achieving a free cash flow conversion target of 85% or more further reinforces its positive financial outlook. GEHC faces competition from prominent players in the medical technology industry, including Philips Healthcare, Draeger, Mindray, Masimo, and Baxter. In specific segments, GEHC competes with Siemens Healthineers, Canon, Fujifilm, Carestream, Hologic, and other companies. Despite competition, GEHC's comprehensive product portfolio, customer-focused approach, and commitment to innovation position it well in the market. GE Healthcare stands out from its competitors in the healthcare sector due to its robust portfolio of cutting-edge products and data-driven solutions. The company's commitment to innovation and advanced technologies enables it to offer unique offerings that address the evolving needs of the industry. One key area where GEHC excels is precision health. Leveraging advancements in genomics, personalized medicine, and targeted therapies, GEHC develops tailored solutions that provide precise and effective treatments for patients. For example, its innovative imaging technologies, such as magnetic resonance imaging (MRI) and computed tomography (CT), enable high-resolution visualization of anatomical structures, aiding in the accurate diagnosis and monitoring of various medical conditions. Moreover, GEHC is at the forefront of the digital revolution in healthcare. By harnessing the power of artificial intelligence (AI) and machine learning, GEHC's products analyze vast amounts of patient data to deliver more accurate diagnoses and treatment decisions. For instance, its AI-powered imaging software can detect and analyze anomalies in medical images, helping clinicians detect diseases at an early stage and enhance treatment outcomes. This data-driven approach not only improves patient care but also increases operational efficiency in healthcare facilities. GEHC's commitment to delivering innovative solutions is further reflected in its diverse product offerings. The company provides a wide range of medical devices, including ultrasound systems, patient monitors, anesthesia machines, and diagnostic imaging equipment. These products are designed to meet the unique needs of healthcare providers and patients, empowering clinicians to make informed decisions and improving patient outcomes. Based on a valuation analysis using trading multiples of similar companies, GEHC's value is estimated to range from $55 billion to $81 billion. Taking the midpoint of this range, the company's estimated enterprise value (EV) is $64 billion, suggesting a potential stock price of $125. This valuation indicates a significant upside potential of at least 66% within 18 to 24 months from the current price. With its strong market position, growth opportunities, and commitment to advancing healthcare, GEHC presents an attractive investment prospect. GE Healthcare is a leading global medical technology and digital solutions company with a clear mission to transform healthcare. With its diverse portfolio of products, services, and solutions, GEHC is well-positioned to capitalize on the growing demand for precision health, digitization, and improved access to healthcare. The company's financial performance, management incentives, and competitive landscape further support its growth potential. Considering the estimated valuation, GE Healthcare's stock price has the potential to increase significantly in the next 1.5 to 2 years, offering investors an opportunity for substantial returns.
NASDAQ:GEHCLong
by moonypto
UPDATE: Life Health Care exceeded our targets big timeLife Health Care was presenting a simple Head and Shoulders with a usual drop for a short. The price started off well then went to the entry. Wake up and not only did it go past R15.96 target... The market opened aty R10.80 exceeding our expectations and profits. It's these trades that we absolutely love and can't help but get excited when things go extraordinary to our favour. Now there is a W Formation and the price has broken up. So looking at a Medium Probability setup, we can expect the price to head to R14.29.
JSE:LHCLong
by Timonrosso
PILL 3x Leverage Medical/ Pharma ETF for swing LONGAMEX:PILL On the 4H Chart, current market price is sitting on the support of order blocks and the EMA200, while in an uptend from a double bottom in the sprint. It is moving into the high volume area of the voluxme profile. For the swing trade, the stop loss is $0.10 below the EMA200 while the targets are marked based on a combination of the horizontal resistances of prior swing pivots along with sell order blocks and the structure of the volume profile. Accordingly, this trade risks $0.60 for about $ 4 to $ 5 of upside making for an excellent swing setup especially since healthcare, medical and pharmacueticals are known to be recession resilient and ETFs are inherently diversified making leveraging a risk probably worth taking.
AMEX:PILLLong
by AwesomeAvani
In 3 Months every month end 10 % for 90 Days Say What? Have lookAchyut Healthcare Ltd is a pharmaceutical trading company that was established in 1996 and is based in Ahmedabad, Gujarat. The company trades in pharmaceutical products, medical devices, and APIs. It manufactures tablets, capsules, oral liquids, and injectables, and also customizes products for domestic and international markets. looking for 59 price in upcoming days of 90 in ACHYUT FROM TODAY 9 APRIL 24 CMP 44.70 MAIL US FOR MORE
BSE:ACHYUTLong
by EasyLife_Advisor
XLV is in tight equilibrium; will break soonAMEX:XLV has formed a five-week equilibrium. The price contraction is already quite tight, indicating that this equilibrium could break very soon. The context is highly bullish: the XLV price is on a weekly uptrend, and the broader market is also showing strong performance. The odds are in favor of an upside breakout. On the chart, there is an example of a possible trade. Please note that while I’m not a fan of diagonal levels, I’ve drawn the triangle solely to illustrate the idea of equilibrium Disclaimer I don't give trading or investing advice, just sharing my thoughts.
AMEX:XLVLong
by hermes_trisme
UNITED HEALTH Time to buy again?Last time we looked into United Health (UNH) we gave a strong buy signal (October 03 2023, see chart below), which turned out to be very successful: After getting rejected on Resistance 3, the stock started to decline structurally within a Channel Down. It is a pattern similar to the Channel Down of November 2022 - March 2023, which was again formed after UNH got rejected within the 2-year Resistance Zone, like it happened this time. There is a high symmetry these past 2 years within the Resistance and Support Zones, so we expect the price to act accordingly. As a result, having already formed a 1D Death Cross, we expect the price to make one last Low towards the Support Zone (as long as the 1D MA50 holds as Resistance) and then rebound, which is what took place on March 10 2023, above the 0.618 Fibonacci retracement level. As a result, we will time our buy accordingly and target $517.00 (Fib 0.618). An additional buy signal would be if the 1W RSI makes a Double Bottom, similar again to March 10 2023. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:UNH
by TradingShot
ELI LILLY Going to $1050 but after a 1D MA50 correction.Eli Lilly (LLY) has basically turned sideways since the February 16 High. The dominant pattern is a Channel Up since the March 07 2023 Low and can be divided into 3 Bullish Waves that delivered rallies between +45% and +52%. Every time the price hit the 1D MA50 (blue trend-line), it was a buy opportunity. The 1D RSI in particular has a Buy Zone, which coincided with all those dip buy opportunities within the Channel Up. As a result, since the stock has already completed a +45% rise from the October 31 2023 Low, we do expect a pull-back to start soon towards the RSI Buy Zone, but only after it rises a little again and forms a Lower High on the RSI, which would be consistent with the previous top formation on the Channel Up. In any case, at any point the RSI hits its Buy Zone, we will position ourselves with a long and aim for a new +45% rise. Rough target from the current projection is $1050. Notice how efficiently the peak and bottom formations are caught by the Sine Waves. A very symmetric pattern for the long-term indeed. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
Dr Lal Pathlabs Ltd can it double in one year?Dr Lal Pathlabs one of the largest players of healthcare industry in India has a beaten down stock price currently. It is approximately 53.29% down from it's lifetime high. There is not a single reason for such stock price. The company is posting good results and is consistently showing profits. But the stock is highly undervalued. It is a good time to buy it as the current levels make it a precious deal to make. Hope you like my analysis. Please do your own study before investing. Do like and follow and share among your family and friends. Thank you.
NSE:LALPATHLABLong
by ronak16125